Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI technique aims to spare healthy lung during cancer radiation

NCT ID NCT05302817

Symptom relief Sponsor: Xemed LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested whether a special MRI scan using hyperpolarized xenon gas could help doctors plan radiation therapy for non-small cell lung cancer. The goal was to map which parts of the lung are working well so radiation can avoid them, potentially reducing side effects like breathing trouble. Only 9 patients were enrolled before the study was terminated, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyperpolarized xenon-129 MRI
What this could lead to
If successful, this imaging technique could help doctors plan radiation therapy to avoid damaging healthy lung tissue, potentially reducing breathing problems and improving quality of life after treatment.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. The approach may not work for all patients, and inhaling hyperpolarized xenon carries unknown risks in people with severely damaged lungs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

9 people

The number who actually took part.

Started

Mar 2023

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients over 18 years with a diagnosis of non-small lung cancer and planned for a definitive course of radiation therapy. * Preferred patients will have had successful radiation therapy for a prior lung cancer and developed a secondary lung cancer for which are to be treated. * Other de-nuovo lung cancer patients planned for radiation therapy with lung heterogeneity from natural co-morbidities (e.g., COPD stage 3+). Exclusion Criteria: * Patients less than 18 years old * Patients known to be pregnant - a positive pregnancy test will be used to respectively exclude pregnant patients, * Any known contraindication to MRI examination * Anyone with an implanted metal device * Inability to provide informed consent * A language, communication, cognitive or behavioral impairment that might interfere with fully informed participation in the study. * History of uncompensated organ failure (i.e. organ failure that is not stabilized through medical intervention), which will be assessed by the PI. * Homelessness or other unstable living situation * Active drug or alcohol dependence * Claustrophobia * Subjects weighting more than 300 pounds. * Subjects with chest size larger than the bore of MRI machine can accommodate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, non-small-cell lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, non-small-cell lung

Contacts and locations

Locations

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.